Consultation Paper on a Methodology for Determining the Benchmark Price for Prostheses in Australian Public Hospitals
Date published: 18 October 2021
The Independent Hospital Pricing Authority (IHPA) primary function is to calculate and deliver an annual national efficient price of public hospital services.
The 2021–22 Federal Budget, released in May 2021, included a measure to modernise and improve the private health insurance Prostheses List.
Under this measure, the Department of Health will implement reforms in conjunction with IHPA to reduce the cost of medical devices used in the private health sector and streamline access to new medical devices.
IHPA developed the Consultation Paper on a Methodology for Determining the Benchmark Price for Prostheses in Australian Public Hospitals to seek feedback from stakeholders on the proposed approach for establishing the benchmark price for prostheses. Public consultation was open from Monday 6 September 2021 to Friday 1 October 2021.
The feedback and comments received through the consultation process will be incorporated into the Methodology for Determining the Benchmark Price for Prostheses in Australian Public Hospitals.
The following formal submissions have been made public.
- Abbott Medical Australia
- Alcon Laboratories (Australia)
- Arthrex Australia
- Australian Medical Association
- Baxter Healthcare
- Bupa Asia Pacific
- Cabrini Health
- Catholic Health Australia
- Device Technologies
- Johnson and Johnson Medical
- MatOrtho Australia
- Medical Technology Association of Australia
- Medtronic Australasia
- Members Health Fund Alliance
- MicroPort CRM
- Private Healthcare Australia
- Ramsay Health Care Australia
- Royal Australian and New Zealand College of Ophthalmologists
- Stryker South Pacific